Published in Cancer Weekly, April 10th, 1995
The Phase I studies carried out by clinical investigators in England concluded that AG337 was well tolerated up to doses that produced anti-tumor effects in several patients.
In one study, Dr. Hilary Calvert and colleagues at the University of Newcastle upon Tyne administered escalating doses of AG337 as a five-day infusion every three...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.